[1] Stein H, Mason DY, Gerdes J, et al.The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells[J]. Blood, 1985, 66(4): 848-858. [2] Willemze R, Jaffe ES, Burg G, et al.WHO-EORTC classification for cutaneous lymphomas[J]. Blood, 2005, 105(10): 3768-3785. [3] 代湘云, 吴涛, 白海. 原发性皮肤间变大细胞淋巴瘤治疗进展[J]. 肿瘤学杂志, 2017, 23(8): 711-714. [4] Lynch RC, Gratzinger D, Advani RH.Clinical impact of the 2016 update to the WHO Lymphoma Classification[J]. Curr Treat Options Oncol, 2017, 18(7): 45-53. [5] 黄长松, 张婧, 程波, 等. ALK蛋白阴性的原发性皮肤CD30+间变大细胞淋巴瘤[J]. 临床皮肤科杂志, 2018, 47(12): 789-791. [6] Chen RF, Chen CT, Liao HT, et al.Primary cutaneous anaplastic large cell lymphoma of the face presenting as posttraumatic maxillary sinusitis[J]. J Craniofac Surg, 2008, 19(6): 1597-1599. [7] Montemarano AD, Rowe JE, Benson PM, et al.KI-1 (CD30)-positive anaplastic large cell lymphoma mimicking an infectious granuloma[J]. Int J Dermatol, 1995, 34(11): 790-793. [8] 侯宇航, 周晋, 赵艳红, 等. 间变大细胞淋巴瘤的临床进展[J]. 现代生物医学进展, 2014, 14(13): 2557-2559. [9] Sica A, Vitiello P, Ronchi A, et al.Primary cutaneous anaplastic large cell lymphoma (pcALCL) in the elderly and the importance of sport activity training[J]. Int J Environ Res Public Health, 2020, 17(3): 839-851. [10] Scarisbrick JJ, Calonje E, Orchard G, et al.Pseudocarcinomatous change in lymphomatoid papulosis and primary cutaneous CD30+ lymphoma: a clinicopathologic and immunohistochemical study of 6 patients[J]. J Am Acad Dermatol, 2001, 44(2): 239-247. [11] Gerami P, Wickless SC, Rosen S, et al.Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma[J]. J Am Acad Dermatol, 2008, 59(2): 245-254. [12] Tomaszewski MM, Moad JC, Lupton GP.Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood[J]. J Am Acad Dermatol, 1999, 40(5 Pt 2): 857-861. [13] Martín JM, Ricart JM, Monteagudo C, et al.Primary cutaneous CD30+ anaplastic large-cell lymphomas mimicking keratoacanthomas[J]. Clin Exp Dermatol, 2007, 32(6): 668-671. [14] Kempf W.CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators[J]. J Cutan Pathol, 2006, 33(Suppl 1): 58-70. [15] Saini S, Dettore AJ, Bhambhani KJ, et al.Selective IgM deficiency in CD30+ cutaneous lymphoproliferative disorder[J]. J Pediatr Hematol Oncol, 2011, 33(4): e156-e159. [16] Lin JH, Lee JY.Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia[J]. J Cutan Pathol, 2004,31(6):458-461. [17] 吴捷, 彭旭佳, 刘强.复合性原发皮肤间变大细胞淋巴瘤和霍奇金淋巴瘤一例及文献复习[J]. 上海医学, 2009, 32(8):738-740, 762. [18] Kume M, Kiyohara E, Aoyama R, et al.Primary cutaneous anaplastic large cell lymphoma with rapid liver infiltration after spontaneous resolution of the primary lesion[J]. J Dermatol, 2020, 47(5): e190-e191. [19] Mencía-Gutiérrez E, Gutiérrez-Díaz E, Salamanca J, et al.Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL)[J]. Int J Dermatol, 2006,45(6):766-769. [20] Burg G, Kempf W, Kazakov DV, et al.Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature[J]. Br J Dermatol, 2003, 148(3): 580-586. [21] Sheehy O, Catherwood M, Pettengell R, et al.Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis[J]. Leuk lymphoma, 2009, 50(8): 1389-1391. [22] de Kan R, van 't Veer MB. Clinical features of CD30 (Ki-1) positive anaplastic large-cell lymphoma (ALCL). Review of the literature[J]. Neth J Med, 1993, 43(5-6): 277-284. [23] Courville P, Wechsler J, Thomine E, et al.Pseudoepitheliomatous hyperplasia in cutaneous T-cell lymphoma. A clinical, histopathological and immunohistochemical study with particular interest in epithelial growth factor expression. The French Study Group on Cutaneous Lymphoma[J]. Br J Dermatol, 1999, 140(3): 421-426. [24] Beljaards RC, Kaudewitz P, Berti E, et al.Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients[J]. Cancer, 1993, 71(6): 2097-2104. [25] Kempf W, Dummer R, Burg G.Approach to lymphoproliferative infiltrates of the skin. The difficult lesions[J]. Am J Clin Pathol, 1999, 111(1 Suppl 1): S84-S93. [26] Top H, Aygit C, Sarikaya A, et al.Evaluation of maxillary sinus after treatment of midfacial fractures[J]. J Oral Maxillofac Surg, 2004, 62(10): 1229-1236. [27] Vardiman JW.The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms[J]. Chem Biol Interact, 2010, 184(1-2): 16-20. [28] Willemze R, Cerroni L, Kempf W, et al.The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas[J]. Blood, 2019, 133(16): 1703-1714. [29] Reginelli A, Belfiore MP, Russo A, et al.A Preliminary study for quantitative assessment with HFUS (high- frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: interdisciplinary team experience[J]. Curr Radiopharm, 2020, 13(1): 48-55. [30] Lee WJ, Moon IJ, Lee SH, et al.Cutaneous anaplastic large-cell lymphoma (ALCL): a comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site[J]. J Am Acad Dermatol, 2016, 74(6): 1135-1143. [31] Kharfan-Dabaja MA, Kumar A, Ayala E, et al.Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation[J]. Biol Blood Marrow Transplant, 2017, 23(11): 1826-1838. [32] Sugiyama H, Asagoe K, Morizane S, et al.Leukocyte common antigen-negative, aggressive cutaneous anaplastic large cell lymphoma with prominent pseudocarcinomatous hyperplasia[J]. Eur J Dermatol, 2008, 18(1): 74-77. [33] Prince HM, Kim YH, Horwitz SM, et al.Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J]. Lancet, 2017, 390(10094): 555-566. [34] Merli M, Frigeni M, Alric L, et al.Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas[J]. Oncologist, 2019, 24(8): e720-e729. [35] Welborn M, Duvic M.Antibody-Based therapies for cutaneous T-cell lymphoma[J]. Am J Clin Dermatol, 2019, 20(1): 115-122. [36] Matutes E.The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms[J]. Int J Lab Hematol, 2018, 40(Suppl 1): 97-103. [37] 韩颖, 石远凯. 淋巴瘤诊断与治疗的十年回顾[J].实用肿瘤杂志, 2017, 32(6): 483-493. [38] Liu HL, Hoppe RT, Kohler S, et al.CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma[J]. J Am Acad Dermatol, 2003, 49(6): 1049-1058. [39] Fauconneau A, Pham-Ledard A, Cappellen D, et al.Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides: a study of 66 cases[J]. Br J Dermatol, 2015, 172(6): 1547-1554. [40] Parás-Bravo P, Salvadores-Fuentes P, Alonso-Blanco C, et al.The impact of muscle relaxation techniques on the quality of life of cancer patients, as measured by the FACT-G questionnaire[J]. PLoS One, 2017, 12(10): e0184147. [41] Calogero A, Sagnelli C, Carlomagno N, et al.Familial polyposis coli: the management of desmoid tumor bleeding[J]. Open Med (Wars), 2019, 14: 572-576. |